AlloVir(US:ALVR)2025-11-12 13:13Financial Position - As of September 30, 2025, Kalaris had cash, cash equivalents, and short-term investments of $77.0 million, a significant increase from $1.6 million as of December 31, 2024, primarily due to the merger with AlloVir in Q1 2025[4] - Kalaris expects its cash resources will be sufficient to fund operations into 2027[4] - The total assets of Kalaris as of September 30, 2025, were $81.2 million, with total liabilities of $39.3 million[16] Research and Development - Research and development expenses for Q3 2025 were $9.1 million, down from $36.0 million in Q3 2024, mainly due to a $32.0 million royalty obligation expense in the previous year[5] - Kalaris is currently enrolling patients in a Phase 1b/2 multiple ascending dose trial of TH103, with initial clinical data from the Phase 1a trial expected by year-end 2025[2] - The newly initiated Phase 1b/2 trial aims to evaluate multiple dose levels of TH103 in up to 80 patients with neovascular age-related macular degeneration (nAMD)[3] - Kalaris has selected KBI Biopharma as its Contract Development and Manufacturing Organization (CDMO) for clinical supply manufacturing of TH103[10] General and Administrative Expenses - General and administrative expenses increased to $3.6 million in Q3 2025 from $1.8 million in Q3 2024, attributed to higher insurance, legal, and professional fees[6] Net Loss - The net loss for Q3 2025 was $11.9 million, compared to a net loss of $38.1 million in Q3 2024, with a total of 18,702,418 shares outstanding[7] Corporate Developments - The company opened a new corporate headquarters in Berkeley Heights, New Jersey, and appointed Matthew Gall as Chief Financial Officer[10]